Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Vishal Manchanda, SVP of institutional research at Systematix Group, told Livemint that even if 0.5% of 40 million use Mounjaro, it would fetch Eli Lilly sales of $1.5 billion annually.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an ...

NMIXX, the dynamic six-member girl group under JYP Entertainment, is set to hold their first official fan meeting, NSWER VACATION, in July. The event marks a special milestone for the group and their ...

It’s old-school preppy at its finest. And not just any prep — we’re talking Lilly Pulitzer prep. Yes, that Lilly Pulitzer. The Palm Beach-born brand known for its punchy prints, scalloped ...

Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty "We are pleased to enter into this collaboration with Lilly to ...

INDIANAPOLIS, IN, USA I June 2, 2025 I Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) ...

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% ...